The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 399-402

  Jakovljevic, M ^a   Pivac, N ^b   Mihaljevic Peles, A ^a   Mustapic, M ^b   Relja, M ^a   Ljubicic, D ^c   Marcinko, D ^a   Muck Seler, D ^b  

^a KBC Zagreb   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c KBC RIJEKA   (Croatia)

Author keywords

Cortisol; Fluphenazine; Olanzapine; Prolactin; Rigidity; Schizophrenia

Indexed keywords

FLUPHENAZINE; HYDROCORTISONE; OLANZAPINE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MUSCLE RIGIDITY; NEUROSECRETORY CELL; OUTCOME ASSESSMENT; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FLUPHENAZINE; HUMANS; HYDROCORTISONE; MUSCLE RIGIDITY; PROLACTIN; SCHIZOPHRENIA;

EID: 33846815091     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.10.007     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
3. Cohrs S., Röher C., Jordan W., Meier A., Huether G., Wuttke W., et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 185 (2006) 11-18
4. Coirini H., Kallstrom L., Wiesel F.A., and Johnson A.E. Modulation of basal ganglia neurotransmission by the classical antipsychotic fluphenazine is due in part to the blockade of dopamine D1-receptors. Mol Brain Res 49 (1997) 197-210
5. Crocker A.D., and Hemsley K.M. An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. Prog Neuro-Psychopharmacol Biol Psychiatry 25 (2001) 573-590
6. Dickson R.A., and Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr Res 35 (1999) S75-S86
7. Dossenbach M.R.K., Folnegovic-Smalc V., Hotujac L.J., Uglesic B., Tollefson G.D., Grundy S.L., et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 28 (2004) 311-318
8. Halbreich U., Kinon B.J., Gilmore J.A., and Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (2003) 53-67
9. Jakovljevic M., Muck-Seler D., Kenfelj H., Plavsic V., Biocina S., Kastratovic D., et al. Basal cortisol, dexamethasone suppression test and platelet 5-HT in recurrent (unipolar) major depression, schizophrenia and schizoaffective disorders. Psychiatr Danub 4 (1991) 389-414
10. Kane J.M. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 11 (2001) s397-s403
11. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
12. Leibenluft E., Fiero P.L., and David R. Effects of menstrual cycle an dependent variables in mood disorder research. Arch Gen Psychiatry 51 (1994) 761-781
13. Mann K., Rossbach W., Müller M., Müller-Siecheneder F., Pott T., Linde I., et al. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31 (2006) 256-264
14. Markianos M., Hatzimanolis J., and Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatemnt with clozapine, olanzapine, risperidone, sulpiride or haloperidol. Eur Arch Psychiatry Clin Neurosci 251 (2001) 141-146
15. Meltzer H.Y., and Nash J.F. VII: Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43 (1991) 587-604
16. Mortimer A.M. Newer and older antipsychotics. A comparative review of appropriate use. CNS Drugs 2 (1994) 381-396
17. Muck-Seler D., Pivac N., Jakovljevic M., and Brzovic Z. Platelet serotonin and plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 45 (1999) 1433-1439
18. Muck-Seler D., Pivac N., Mustapic M., Crncevic Z., Jakovljevic M., and Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 127 (2004) 217-226
19. Nyberg S., Farde L., and Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine on healthy subjects. Neuropsychopharmacology 16 (1997) 1-7
20. Petty R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35 (1999) s67-s73
21. Putzhammer A., Perfahl M., Pfeif L., Ibach B., Johann M., Zitzelsberger U., et al. Performance of diadochokinetic movements in schizophrenic patients. Schizophr Res 79 (2005) 271-280
22. Relja A.M., Petravić D., and Kolaj M. Quantifying rigidity with a new computerized elbow device. Clin Neuropharmacol 19 (1996) 148-156
23. Richelson E., and Souder T. Binding of antypsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68 (2000) 29-39
24. Ryan M.C.M., Sharifi N., Condren R., and Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29 (2004) 1065-1070
25. Seeman T.E., and Robbins R.J. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocrinol Rev 15 (1994) 233-260
26. Tandon R., and Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side-effects. Psychoneuroendocrinology 28 (2003) 1-7
27. Tandon R., Mazzara C., DeQuadro J., Craig K.A., Meador-Woodruff J.H., Goldman R., et al. Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 29 (1991) 953-964